Positive pharma report finds increased funding, productivity and product launches in 2023

26 February 2024
biotech-research

Global biopharma R&D productivity rebounded in 2023, according to a new report.

There were higher composite success rates enabled by industry-wide and regulator adoption of data and tech-driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies, the analysis found.

This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the report, Global Trends in R&D 2024: Activity, Productivity, and Enablers, released by the IQVIA Institute for Human Data Science.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical